ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
|
|
- Collin Davidson
- 6 years ago
- Views:
Transcription
1 ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg karl.swedberg@hjl.gu.se ESC Guidelines for the Diagnosis and Treatment of CHF
2 Key issues in Chronic Heart Failure Chronic Heart Failure (CHF) is Common 2% of the population Dangerous high mortality Disabling high morbidity Costly 2% of health care budget Treatable very successful pharmacological therapy developed ESC Guidelines for the Diagnosis and Treatment of CHF
3 ESC Guidelines for the Diagnosis and Treatment of CHF
4 Classes of recommendations I II IIa IIb III Condition for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective Condition for which there is conflicting evidence and /or a divergence of opinion about the usefulness / efficacy of a procedure or treatment Weight of evidence /opinion is in favour of usefulness / efficacy Usefulness/efficacy is less well established by evidence / opinion Evidence or general agreement that the treatment is not useful/effective and in some cases may be harmful Levels of Evidence A B C Data derived from multiple randomized clinical trials or meta-analyses Data derived from a single randomized trial or large non randomized studies Consensus of opinion of experts and/or small studies, retrospective studies, registries ESC Guidelines for the Diagnosis and Treatment of CHF
5 Relationship between cardiac dysfunction, HF and HF rendered asymptomatic NORMAL CARDIAC DYSFUNCTION CORRECTED OR RESOLVED Therapy CAN be withdrawn without recurrence of symptoms Transient Heart Failure CARDIAC DYSFUNCTION No symptoms Asymptomatic cardiac dysfunction SYMPTOMS Symptoms relieved Therapy CANNOT be withdrawn without recurrence of symptoms HEART FAILURE Symptoms persist Systolic dysfunction THERAPY ESC Guidelines for the Diagnosis and Treatment of CHF
6 Algorithm for Diagnosis of Chronic HF or LV Dysfunction ESC Guidelines for the Diagnosis and Treatment of CHF
7 NT-proBNP and BNP: Synthesis and secretion Stretched cardiac myocyte pre-probnp (134 amino acids) probnp (108 amino acids) signal peptide (26 amino acids) NT-proBNP (1-76) BNP 32 (physiologically active form) blood ESC Guidelines for the Diagnosis and Treatment of CHF
8 Natriuretic Peptides Plasma concentrations of certain natriuretic peptides or their precursors, especially BNP and NTproBNP, are helpful in the diagnosis of heart failure. A low-normal concentration in an untreated patient makes heart failure unlikely as the cause of symptoms. BNP and NT-proBNP have considerable prognostic potential, although evaluation of their role in treatment monitoring remains to be determined. ESC Guidelines for the Diagnosis and Treatment of CHF
9 Echocardiography and Doppler Echocardiography: preferred method for the documentation of cardiac dysfunction at rest. Left ventricular ejection fraction most important assessment to differentiate CHF patients with or without preserved systolic function. Diastolic dysfunction: evidence of abnormal left ventricular relaxation, diastolic distensibility or diastolic stiffness. ESC Guidelines for the Diagnosis and Treatment of CHF
10 Diastolic dysfunction or Preserved Left Ventricular Ejection Fraction (PLVEF) Diastolic heart failure is often presumed to be present when symptoms and signs of heart failure occur in the presence of a PLVEF (normal ejection fraction/normal end-diastolic volume) at rest. Predominant diastolic dysfunction is relatively uncommon in younger patients but increases in importance in the elderly, in particular women, in whom systolic hypertension and myocardial hypertrophy with fibrosis are contributors to cardiac dysfunction. ESC Guidelines for the Diagnosis and Treatment of CHF
11 PLVEF and diastolic dysfunction Diastolic dysfunction PLVEF Hypertension Aortic stenosis Ischaemia Elderly Women Symptomatic Diastolic heart Failure ESC Guidelines for the Diagnosis and Treatment of CHF
12 Non-pharmacological interventions Recommendaions regarding Vaccinations Fluid restrictions Traveling Sexual activity Exercise and training ESC Guidelines for the Diagnosis and Treatment of CHF
13 Euroheart Survey on HF Distribution of Ejection Fraction patients in 115 hospitals in 24 countries Percentage of patients Cleland et al Euroheart Survey EHJ 2003 ESC Guidelines for the Diagnosis and Treatment of CHF Women Men < Left Ventricular Ejection Fraction (%)
14 Survival US Carvedilol Programme Carvedilol n=696 Placebo n=398 Survival COPERNICUS Carvedilol Risk reduction=65% p< Survival Risk reduction=34% p< CIBIS-II II Packer et al (1996) Days Bisoprolol Placebo Time after inclusion (days) Mortality (%) Risk reduction=35% p= MERIT-HF CIBIS-II II Investigators (1999) The MERIT-HF Study Group (1999) p= Months of follow-up Months Placebo Placebo Packer et al (2001) Metoprolol CR Risk reduction=34% ESC Guidelines for the Diagnosis and Treatment of CHF
15 SENIORS All-cause mortality or CV admission 2128 patients >70 years and hospitalised for CHF or LVEF <35% HR 0.86 ( ) Flather et al EHJ 2005 ESC Guidelines for the Diagnosis and Treatment of CHF
16 Beta-blockade in Heart Failure Re-evaluation 2005 Beta-blocking agents are recommended for the treatment of all patients with stable mild, moderate and severe heart failure from ischaemic and non-ischaemic origin.on standard treatment including ACE inhibition and diuretics Level of evidence A, class I ESC Guidelines for the Diagnosis and Treatment of CHF
17 COMET: Primary outcome: Mortality 3,029 pts with CHF class II-III III and LVEF <35% Mortality (%) 40 Metoprolol tartrate Carvedilol Hazard ratio 0.83, 95% CI , p= Poole-Wilson et al Lancet 2003 ESC Guidelines for the Diagnosis and Treatment of CHF
18 Beta-blockade in heart failure Re-evaluation 2005 Beta-blocking agents are recommended for the treatment of all patients with stable mild, moderate and severe heart failure from ischaemic and non-ischaemic origin.on standard treatment including ACE inhibition and diuretics Level of evidence A, class I Only bisoprolol, carvedilol, metoprolol CR and nebivolol can be recommended Metoprolol tartrate is not recommended for use in treatment of CHF ESC Guidelines for the Diagnosis and Treatment of CHF
19 Renin-angiotensin in McMurray et al Circ 2004 Angiotensinogen aldosterone system Vasoconstriction Cell growth Na+/H 2 O retention Sympathetic activation Renin Angiotensin I AT 1 Angiotensin II ACE Aldosterone AT 2 Cough, Angioedema Benefits? Bradykinin Inactive Fragments Vasodilation Antiproliferation (kinins) ESC Guidelines for the Diagnosis and Treatment of CHF
20 SAVE, AIRE, TRACE SOLVD ACE-inhibitor trials in heart failure/lvdysfunction-mortality Randomized large (>1000 patients), long-term (1 year) trials ACE-inhibitor vs placebo patients in 4 trials Flather et al Lancet Total Better ACE-inhibitor Worse ESC Guidelines for the Diagnosis and Treatment of CHF
21 ACE-inhibitors ACE-inhibitors are recommended as first-line therapy in patients with reduced LV systolic function (LVEF <40-45%) (Level of evidence A, class I) In the absence of fluid retention ACE-inhibitors should be given first, in the presence of fluid retention together with diuretics (Level of evidence B, class I) ACE-inhibitors should be up-titrated to the dosages shown to be effective in large trials They should not be titrated based on symptomatic improvement ESC Guidelines for the Diagnosis and Treatment of CHF
22 VAL-HeFT 5010 pts in NYHA class II (61.7%), III (36.2%) or IV (3.1%) Mean EF 27% and mean age 62 years Randomized to placebo/valsartan Background: ACE-I I 92.3%, Beta-blocker 35.5% Placebo Valsartan n=2511 n=2499 RR (C.I.) p Primary endpoints All cause mortality 484 (19.4%) 495 (19.7%) ( ) Mortality and all cause hosp. 801 (32.1%) 723 (28.8%) ( ) 0.96) Cohn et al NEJM 2001 ESC Guidelines for the Diagnosis and Treatment of CHF
23 Val-HeFT HeFT: : All-cause mortality or morbidity Event-free probability RR=13.3% p= Months Valsartan Placebo Cohn et al NEJM 2001 ESC Guidelines for the Diagnosis and Treatment of CHF
24 Subgroups: ACE-inhibitors and beta-blockers Cohn et al NEJM 2001 ESC Guidelines for the Diagnosis and Treatment of CHF
25 CHARM Programme 3 component trials (n=7601) comparing candesartan to placebo in patients with symptomatic heart failure CHARM Alternative n=2028 LVEF 40% ACE-inhibitor intolerant CHARM Added n=2548 LVEF 40% ACE-inhibitor treated CHARM Preserved n=3025 LVEF >40% ACE-inhibitor treated/not treated Primary outcome for each trial: CV death or CHF hospitalisation Primary outcome for Overall Programme: All-cause death ESC Guidelines for the Diagnosis and Treatment of CHF
26 Death % 35 CHARM-Overall: All-cause death Placebo 945 (24.9%) Candesartan886 (23.3%) years Number at risk Candesartan Placebo HR 0.91 (95% CI ), p=0.055 Adjusted HR 0.90, p=0.032 Pfeffer et al Lancet 2003 ESC Guidelines for the Diagnosis and Treatment of CHF
27 CHARM - Low EF (Alternative+Added): All-cause death Death % 40 Placebo Young et al Circ One year HR 0.67 <0.001 Candesartan 10 HR 0.88 (95% CI ) 0 p=0.018 Number at risk years Candesartan Placebo ESC Guidelines for the Diagnosis and Treatment of CHF
28 CHARM-Added: Prespecified subgroups: CV death or CHF hospitalization Candesartan Placebo Beta- Yes 223/ /711 blocker No 260/ /561 p-value for treatment interaction 0.14 Recom. Yes 232/ /648 dose of No 251/ /624 ACE inhib All patients 483/ /1272 McMurray et al Lancet Candesartan Hazard Placebo better ratio better ESC Guidelines for the Diagnosis and Treatment of CHF
29 Proportion of patients (%) CHARM-Preserved Investigator Reported CHF Hospitalizations Yusuf et al Lancet 2003 Number of episodes 700 HR = 15% RRR = 29% p=0.017 Patients hospitalized ESC Guidelines for the Diagnosis and Treatment of CHF p=0.014 Placebo Candesartan Hospitalizations
30 Pfeffer et al Lancet 2003 Proportion of patients (% ) CHARM-Overall: CHF hospitalizations RR 21% p< Patients hospitalized Number of episodes ESC Guidelines for the Diagnosis and Treatment of CHF Placebo Candesartan RR 28% p< Hospitalizations
31 Survival post-mi according to presence of heart failure: GRACE Registry Mortality % 0.3 Heart failure during hospitalization Heart failure at admission No heart failure at admission Months Steg et al Circulation 2004 ESC Guidelines for the Diagnosis and Treatment of CHF
32 Probability of Event Months Mortality by Treatment Pfeffer,, McMurray, Velazquez, et al. N Engl J Med 2003;349 Captopril Valsartan Valsartan + Captopril Valsartan vs Captopril: HR = 1.00; P = Valsartan + Captopril vs Captopril: HR = 0.98; P = Captopril Valsartan Valsartan+Cap ESC Guidelines for the Diagnosis and Treatment of CHF
33 ARBs and CHF Update 2005 In patients with systolic dysfunction ARBs are a good alternative to ACE-inhibition in symptomatic patients intolerant to ACE-inhibitors to improve morbidity and mortality (level of evidence B, class I) ARBs and ACE-inhibitors have similar efficacy in CHF (level of evidence B, class I) After acute myocardial infarction with signs of heart failure or left ventricular dysfunction, ARBs have similar efficacy to ACE-inhibitors (level of evidence B, class I) ESC Guidelines for the Diagnosis and Treatment of CHF
34 ARBs and CHF Update 2005 ARBs can be considered in combination with ACE-inhibitors in patients who remain symptomatic, to reduce mortality (level of evidence B, class IIa) and hospital admissions for heart failure (level of evidence A, class I) ESC Guidelines for the Diagnosis and Treatment of CHF
35 EPHESUS: Total Mortality 6642 pts with AMI, LVEF <40%, Rales, Standard Therapy Cumulative Incidence (%) Placebo Eplerenone RR = 0.85 (95% CI, ) p= Months Since Randomization Pitt et al NEJM 2003 ESC Guidelines for the Diagnosis and Treatment of CHF
36 10 EPHESUS: Sudden Cardiac Death All Patients 16 Patients with Baseline Ejection Fraction 30% Cumulative Incidence (%) Placebo Eplerenone RR = 0.79 (95% CI, ) p= Months Since Randomization Placebo Eplerenone RR = 0.67 (95% CI, ) p=0.009 Pitt et al NEJM 2003 ESC Guidelines for the Diagnosis and Treatment of CHF
37 Update 2005 and AA Aldosterone receptor antagonist: is recommended in addition to ACE-inhibition, betablockers and diuretics in advanced heart failure (NYHA III-IV) to improve survival and morbidity (level of evidence B, class I) is recommended in addition to ACE-inhibition and beta-blockade in heart failure after myocardial infarction with left ventricular systolic dysfunction and signs of heart failure to reduce mortality and morbidity (level of evidence B, class I) ESC Guidelines for the Diagnosis and Treatment of CHF
38 Update 2005 and AA Whether an aldosterone antagonist is of proven benefit in patients with class II heart failure or asymptomatic left ventricular dysfunction remains to be established When symptoms increase, which neurohormonal antagonist to add is difficult to determine ESC Guidelines for the Diagnosis and Treatment of CHF
39 Pharmacological therapy of heart failure due to Left Ventricular Systolic Dysfunction NYHA I For Survival/Morbidity mandatory therapy Cont. ACE-inhibitor/ARB if ACEinhibitor intolerant, continue aldosterone antagonist if post-mi add beta-blocker if post-mi For Symptoms reduce / stop diuretic NYHA II ACE-inhibitor as first-line treatment/arb if ACE-inhibitor intolerant add betablocker and aldosterone antagonist if post MI +/- diuretic depending on fluid retention NYHA III ACE-inhibitor plus ARB or ARB alone if ACE intolerant beta-blocker add aldosterone antagonist + diuretics + digitalis If still symptomatic NYHA IV Continue ACE-inhibitor/ARB beta-blocker Aldosterone antagonist +diuretics + digitalis + consider temporary inotropic support ESC Guidelines for the Diagnosis and Treatment of CHF
40 Treatment of patients with preserved ejection fraction (PSEF) ACE-inhibitors may improve relaxation and cardiac distensibility directly and may have long-term effects through their anti-hypertensive effects and regression of hypertrophy and fibrosis. Diuretics may be necessary when episodes with fluid overload are present, but should be used cautiously so as not to lower preload excessively. Beta-blockade could be instituted to lower heart rate and increase the diastolic period. Verapamil-type calcium antagonists may be used for the same. A high dose of an ARB may reduce hospitalizations. ESC Guidelines for the Diagnosis and Treatment of CHF
41 Nurse lead clinics: Survival 106 patients randomized to control or intervention Cumulative survival p= Days of follow-up Intervention Control Strömberg et al, EHJ 2003 ESC Guidelines for the Diagnosis and Treatment of CHF
42 Care Management An organised system of specialist heart failure care improves symptoms and reduces hospitalisations (level of evidence A, class I) and mortality (level of evidence B, class IIa) It is likely that the optimal model will depend on local circumstances and resources (level of evidence C, class I) ESC Guidelines for the Diagnosis and Treatment of CHF
43 COMPANION: Primary Endpoint All-cause mortality or all-cause hospitalization 1520 pts in CHF NYHA class III-IV IV randomized to conv. treatment, CRT or CRT+ICD Bristow et al NEJM 2004 ESC Guidelines for the Diagnosis and Treatment of CHF
44 CARE-HF 813 pts with with CHF and LV dyssynchrony and/or QRS > 150 msec Randomized to CRT or control (open) Cleland et al NEJM, 2005 Mortality or CV hospitalisation Mortality ESC Guidelines for the Diagnosis and Treatment of CHF
45 Pacing/Resynchronization(CRT) Conventional right ventricular pacing has no established role in the treatment of heart failure, except for conventional bradycardia indication (level of evidence A, class I) Bi-ventricular pacing can be considered in patients with reduced ejection fraction and ventricular dyssynchrony (QRS width >120 msec) and who remain symptomatic (NYHA III-IV) despite optimal medical therapy to improve symptoms and hospitalizations (level of evidence A, class I) Mortality (level of evidence B, class I) ESC Guidelines for the Diagnosis and Treatment of CHF
46 SCD-HeFT ESC Guidelines for the Diagnosis and Treatment of CHF
47 SCD-HeFT 2521 pts with CHF class II-III III and LVEF<35% Randomized to placebo, amiodarone or single-lead lead, shock-only only ICD Bardy et al NEJM, 2005 ESC Guidelines for the Diagnosis and Treatment of CHF
48 ICD Implantation of an ICD in combination with bi-ventricular pacing can be considered in patients who remain symptomatic with severe heart failure NYHA class III-IV with LVEF <35% and QRS duration > 120 msec to improve mortality or morbidity (level of evidence B, class IIa) ICD therapy is recommended to improve survival in patients after cardiac arrest or who have sustained ventricular tachycardia, with reduced systolic left ventricular function (level of evidence A, class I) ICD implantation is reasonable in selected symptomatic patients with left ventricular ejection fraction <30-35%, not within 40 days of a myocardial infarction, on optimal background therapy including ACE-inhibitor, ARB, betablocker and an aldosterone antagonist, where appropriate, to reduce sudden death (level of evidence A, class I) ESC Guidelines for the Diagnosis and Treatment of CHF
49 Conclusions Treatment of CHF with a combination of various neuroendocrine antagonists has resulted in substantial improvements in outcomes in this malignant syndrome over a relatively short period of time. Implementation of ESC Guidelines will provide optimal evidence based therapy. ESC Guidelines for the Diagnosis and Treatment of CHF
Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationBeta-blockers in heart failure: evidence put into practice
Beta-blockers in heart failure: evidence put into practice John McMurray Professor of Medical Cardiology, University of Glasgow & Consultant Cardiologist,Western Infirmary, Glasgow, UK Eugene Braunwald
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationheart failure John McMurray University of Glasgow.
A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationThe role of angiotensin II receptor blockers in the management of heart failure
European Heart Journal Supplements (2005) 7 (Supplement J), J10 J14 doi:10.1093/eurheartj/sui057 The role of angiotensin II receptor blockers in the management of heart failure John J.V. McMurray* Department
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationContemporary Advanced Heart Failure Therapy
Contemporary Advanced Heart Failure Therapy Andrew Boyle, MD Professor of Medicine Medical Director of Advanced Heart Failure Thomas Jefferson University Philadelphia, PA Audience Response Question 40
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationHeart Failure Management Update
Heart Failure Management Update Rafique Ahmed, MD, PhD, FACC, FCPS Consultant Cardiac Electrophysiologist Baltimore, Maryland, USA Heart Failure - Definition The situation when the heart is incapable of
More informationThe Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego
The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More informationBehandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion
Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion Professor Dr. med. Roger Hullin Leiter Programm für Schwere Herzinsuffizienz, VAD & Herztransplantation Suisse Romande Klinik
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationHeart Failure Update. Michael Fu. Professor, Överläkare
Heart Failure Update Michael Fu Professor, Överläkare Update in Diagnosis Update in Pharmacological Treatment Update in Device Therapy Heart Failure in the Elderly Put Guidelines into Clinical Practice
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationHeart Failure. Jay Shavadia
Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary
More informationWomen s Heart Health: Holistic Approaches Throughout the Lifetime - Key Differences in Heart Failure in Women
Women s Heart Health: Holistic Approaches Throughout the Lifetime - Key Differences in Heart Failure in Women C. Noel Bairey Merz MD Medical Director and Barbra Streisand Women s Heart Center Preventive
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationTERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018
TERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018 Carlo Lombardi Cattedra di Cardiologia Università e Spedali Civili di Brescia All-cause mortality in the European
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationFaiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm
Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring
More informationeplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd
eplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd 08 June 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationImplantation of a CRT-Pacemaker Rather than CRT-Defibrillator is Usually Preferred
Implantation of a CRT-Pacemaker Rather than CRT-Defibrillator is Usually Preferred Professor John GF Cleland University of Hull Kingston-upon-Hull United Kingdom Conflict of Interest: Funding or Speakers
More informationEpidemiology of Symptomatic Heart Failure in the U.S.
William T. Abraham, MD, FACP, FACC, FAHA, FESC Professor of Medicine, Physiology, and Cell Biology Director, Division of Cardiovascular Medicine Deputy Director Davis Heart and Lung Research Institute
More informationNeurohormonal blockade: is there still room to go?
Neurohormonal blockade: is there still room to go? M.Birhan YILMAZ, MD, FESC, FACC, FHFA Professor of Cardiology, Cumhuriyet University Sivas, TURKEY President of Heart FailureWG of Turkish Society of
More informationThe value of angiotensin-converting enzyme (ACE) inhibitors
New Drugs and Technologies Which Inhibitor of the Renin Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? John J.V. McMurray, MD; Marc A. Pfeffer, MD, PhD; Karl
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationImpact of the African American Heart Failure Trial (A-HeFT): Guideline-based Therapy in Blacks with Heart Failure 2016
Impact of the African American Heart Failure Trial (A-HeFT): Guideline-based Therapy in Blacks with Heart Failure 2016 National Minority Quality forum APRIL 11, 2016 Washington,D.C. Keith C. Ferdinand,
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationDiastolic Heart Failure
Diastolic Heart Failure Presented by: Robert Roberts, M.D., FRCPC, MACC, FAHA, FRSC Professor of Medicine and Chair ISCTR University of Arizona, College of Medicine Phoenix Scientist Emeritus and Advisor,
More informationDIASTOLIC HEART FAILURE
DIASTOLIC HEART FAILURE M Mohsen Ibrahim, MD Alexandria, Proposed Criteria for Diastolic Heart Failure ESC Working Group (EHJ 1998) CHF signs/symptoms EF 45% Hemodynamic or echo evidence of diastolic dysfunction
More informationSacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC
Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC Head of Cardiology Medical Manager / CV Program CHUM Disclosure Statement Within the past two years: I have had an
More informationΦαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας. Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ.
Φαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ.Γεννηματάς Clinical Trials on Fibrinolysis N = 61.41 AMI pts, ( GUSTO I, GUSTOIIb,
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationThe burden of disease in patients with. What s New. Heart Failure? In this article:
What s New in Heart Failure? A large part of the population is at risk for congestive heart failure. With one-year mortality rates approaching 40%, it is crucial to understand the newest and best treatment
More informationPosition Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE
Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE Over 8,000 patients have been studied in two well-designed placebo-controlled outcome-driven clinical trials to evaluate the
More informationTerapia Farmacologica della Insufficienza Cardiaca Cronica: è in arrivo una rivoluzione? Gennaro Cice
Terapia Farmacologica della Insufficienza Cardiaca Cronica: è in arrivo una rivoluzione? Gennaro Cice Cattedra di Cardiologia Seconda Università di Napoli 60 CONGRESSO NAZIONALE SIGG NAPOLI, 25-28 NOVEMBRE
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST TAKE HOME MESSAGES FROM RECENT HEART FAILURE CLINICAL TRIALS How to use aldosterone blockers? Faiez Zannad INSERM, U961 and Clinical Investigation Center CHU, Heart
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationHeart Failure Dr Eric Klug Sunninghill, Sunward Park, CM Johannesburg Academic Hospital
Heart Failure 2012 Dr Eric Klug Sunninghill, Sunward Park, CM Johannesburg Academic Hospital PRELOAD COWS Reduction in milk production INOTROPY & HEART RATE AFTERLOAD DISTRIBUTION NETWORK THE CLASSIC APPROACH
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationNew Strategies For Treating Patients With Chronic Heart Failure
New Strategies For Treating Patients With Chronic Heart Failure Barry Greenberg MD Professor of Medicine Director, Advanced Heart Failure Treatment Program University of California, San Diego Disclosures
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationMedical Management of Heart Failure
Medical Management of Heart Failure Louisville Symposium on Heart Disease in Women June 28, 2014 Andrew J. Lenneman, MD Assistant Professor of Medicine University of Louisville Division of Cardiovascular
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationHeart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than most cancers
Patients in US (millions) Heart Failure (HF): Scope of the Problem 1 4 2 3.5 4. 1. 1991 21 237 US prevalence*: 5. million US annual incidence: 7, Annual mortality: 22,754 5-1% depending on severity Cost:
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationBeyond neuro-hormonal blockade
Beyond neuro-hormonal blockade Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More informationIs Heart Rate a Treatment Target?
Is Heart Rate a Treatment Target? M. Böhm Innere Medizin III (Kardiologie / Angiologie / Internistische Intensivmedizin) Universitätsklinikum des Saarlandes Homburg/Saar michael.boehm@uks.eu Heart Rate
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationRAS Blockade Across the CV Continuum
A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)
More informationNew Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition
New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition Prakash Deedwania, MD, FACC, FACP, FCCP, FAHA Professor of Medicine, UCSF School of Medicine, Director,
More informationReview Article. Pharmacotherapy of Heart Failure with Reduced LVEF. Sachin Mukhedkar, Ajit Bhagwat
Review Article Vidarbha Journal of Internal Medicine Volume 22 January 2017 Pharmacotherapy of Heart Failure with Reduced LVEF 1 2 Sachin Mukhedkar, Ajit Bhagwat ABSTRACT Heart failure with reduced ejection
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationHF and CRT: CRT-P versus CRT-D
HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA
More informationGerasimos Filippatos MD, FESC, FCCP, FACC
Gerasimos Filippatos MD, FESC, FCCP, FACC Head of HF Unit at Athens University Hospital, Greece President (2014-2016) of the HF Association of the European Society of Cardiology (ESC) Served as Chair of
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationSystolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine
Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationSemilogarithmic relation between rest heart rate and life expectancy
The importance of heart rate in heart failure Karl Swedberg Professor of Medicine Department t of emergency and cardiovascular medicine i Sahlgrenska Academy University of Gothenburg, Sweden karl.swedberg@gu.se
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationThe Management of Heart Failure with Preserved Ejection Fraction
The Management of Heart Failure with Preserved Ejection Fraction Andrew JS Coats 1,2 and Louise G Shewan 1,2,3 1. Monash University, Melbourne, Australia; 2. University of Warwick, Coventry, UK; 3. Sydney
More informationNew horizons in HF: potential of new drugs
New horizons in HF: potential of new drugs Marc A. Pfeffer, MD, PhD Dzau Professor of Medicine, Harvard Medical School Cardiovascular Division, Brigham & Women s Hospital Boston, Massachusetts FINANCIAL
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More information12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices. Heart Rate as a Cardiovascular Biomarker
12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices Heart Rate as a Cardiovascular Biomarker Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine,
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationNT-proBNP: Evidence-based application in primary care
NT-proBNP: Evidence-based application in primary care Associate Professor Rob Doughty The University of Auckland, Auckland City Hospital, Auckland Heart Group NT-proBNP: Evidence in Primary Care The problem
More informationAngiotensin receptor blockers in the treatment of heart failure
Heart Failure: Pharmacologic Management Edited by Arthur M. Feldman Copyright 2006 by Blackwell Publishing 4 CHAPTER 4 Angiotensin receptor blockers in the treatment of heart failure Anita Deswal, MD,
More informationHeart Failure. GP Update Refresher 18 th January 2018
GP Update Refresher 18 th January 2018 Heart Failure Dr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More information